KR100275593B1 - 경피 침투 강화제로써 트리아세틴 - Google Patents

경피 침투 강화제로써 트리아세틴 Download PDF

Info

Publication number
KR100275593B1
KR100275593B1 KR1019970707309A KR19970707309A KR100275593B1 KR 100275593 B1 KR100275593 B1 KR 100275593B1 KR 1019970707309 A KR1019970707309 A KR 1019970707309A KR 19970707309 A KR19970707309 A KR 19970707309A KR 100275593 B1 KR100275593 B1 KR 100275593B1
Authority
KR
South Korea
Prior art keywords
triacetin
drug
skin
adhesive
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019970707309A
Other languages
English (en)
Korean (ko)
Other versions
KR19990007786A (ko
Inventor
다니 쿠안
닌아드 에이. 데쉽판다이
시리나바신 벤카테쉬와란
찰스 디. 에버트
Original Assignee
에버트 챨스 디
테라테크인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23704623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100275593(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에버트 챨스 디, 테라테크인코포레이티드 filed Critical 에버트 챨스 디
Publication of KR19990007786A publication Critical patent/KR19990007786A/ko
Application granted granted Critical
Publication of KR100275593B1 publication Critical patent/KR100275593B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019970707309A 1995-04-26 1996-04-08 경피 침투 강화제로써 트리아세틴 Expired - Lifetime KR100275593B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8/429757 1995-04-26
US08/429,757 US5601839A (en) 1995-04-26 1995-04-26 Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US8/429,757 1995-04-26

Publications (2)

Publication Number Publication Date
KR19990007786A KR19990007786A (ko) 1999-01-25
KR100275593B1 true KR100275593B1 (ko) 2000-12-15

Family

ID=23704623

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970707309A Expired - Lifetime KR100275593B1 (ko) 1995-04-26 1996-04-08 경피 침투 강화제로써 트리아세틴

Country Status (18)

Country Link
US (2) US5601839A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0871420B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3228341B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100275593B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN1507918A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR001721A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE205694T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU696777B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2217888C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE122005000013I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0871420T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2163012T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR05C0008I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300200I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ306249A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT871420E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996033678A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA963229B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101975677B1 (ko) 2017-11-20 2019-05-07 양진석 환편기용 보풀 제거장치
KR20200047437A (ko) 2018-10-26 2020-05-07 경상대학교산학협력단 아세틴 화합물의 생물학적 제조 방법

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
ATE277620T1 (de) * 1996-07-15 2004-10-15 Alza Corp Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
WO1998018417A1 (en) * 1996-10-30 1998-05-07 Theratech, Inc. Fatty acid esters of lactic acid salts as permeation enhancers
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
DE19706824C1 (de) * 1997-02-21 1998-03-26 Lohmann Therapie Syst Lts Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
ATE418988T1 (de) * 1997-11-10 2009-01-15 Strakan Int Ltd Penetrationsfördernde und irritationsvermindernde systeme mit testosteron
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
EP1459741A1 (en) * 1997-12-15 2004-09-22 Noven Pharmaceuticals, Inc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with menthylphenidate
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6727401B1 (en) * 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
DE29823343U1 (de) * 1998-03-20 1999-07-15 Schwarz Pharma Ag, 40789 Monheim Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AU3536799A (en) * 1999-04-26 2000-11-10 Lead Chemical Co., Ltd. Percutaneous preparations containing oxybutynin
WO2000076490A2 (en) * 1999-06-10 2000-12-21 Sepracor Inc. Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
ATE273682T1 (de) 1999-06-25 2004-09-15 Durham Pharmaceuticals Ltd Topische formulierungen, die hautpenetrations- mittel enthalten, und ihre verwendung
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
US20010049546A1 (en) * 2000-02-08 2001-12-06 Israel Dvoretzky Multi-purpose drug and heat therapy treatment system
US6436428B1 (en) 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
ES2357699T3 (es) * 2000-04-26 2011-04-28 Watson Pharmaceuticals, Inc. Reducir las experiencias adversas asociada con la terapia de oxibutinina.
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
EP1372708B1 (en) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Vaccine for transcutaneous immunization against travellers' diarrhoea
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030176379A1 (en) * 2001-05-11 2003-09-18 Raoof Araz A. Antisense permeation enhancers
US6913760B2 (en) * 2001-08-06 2005-07-05 New England Medical Hospitals, Inc. Drug delivery composition
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
JP4295467B2 (ja) * 2002-04-12 2009-07-15 日東電工株式会社 貼付剤およびその製造方法
KR100469995B1 (ko) * 2002-05-20 2005-02-05 안국약품 주식회사 천식치료제를 함유한 매트릭스형 패취
JP4323138B2 (ja) * 2002-06-05 2009-09-02 日東電工株式会社 経皮吸収型製剤およびその製造方法
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
WO2004019892A2 (en) * 2002-08-30 2004-03-11 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
DE10251256A1 (de) * 2002-11-04 2004-05-13 Novosis Ag Transdermales Wirkstoffabgabesystem für Oxybutynin
PT1426049E (pt) * 2002-12-02 2005-09-30 Sanol Arznei Schwarz Gmbh Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE602004026173D1 (de) * 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
ES2377932T3 (es) 2003-10-10 2012-04-03 Ferring Bv Formulación farmacéutica transdérmica para minimizar los residuos sobre la piel
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
EP1611882B1 (en) * 2004-06-01 2010-04-07 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP2216018B1 (en) 2004-10-21 2012-04-04 Durect Corporation Transdermal delivery systems
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8372040B2 (en) 2005-05-24 2013-02-12 Chrono Therapeutics, Inc. Portable drug delivery device including a detachable and replaceable administration or dosing element
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
JP5037831B2 (ja) * 2006-02-15 2012-10-03 久光製薬株式会社 凝集力向上及び徐放化の外用貼付剤
JP2009528357A (ja) * 2006-02-27 2009-08-06 ノーヴェン ファーマシューティカルズ インコーポレイテッド アミノ官能性薬剤の投与のための組成物及び方法
WO2007143674A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
TW200817049A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
JP5372523B2 (ja) * 2006-12-28 2013-12-18 科研製薬株式会社 真菌症治療用ゲル組成物
NZ552816A (en) * 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
CA2679316C (en) 2007-03-02 2016-11-29 Teika Pharmaceutical Co., Ltd. Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
US10183001B1 (en) * 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US20100278935A1 (en) * 2007-07-30 2010-11-04 Stacey William C Immune System Modulator Formulation
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
WO2009075324A1 (ja) * 2007-12-12 2009-06-18 Teikoku Seiyaku Co., Ltd. ロキソプロフェン含有水性貼付剤
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
US8404255B2 (en) * 2008-07-29 2013-03-26 Matt Gibson System and method for transdermal drug delivery
US8142592B2 (en) 2008-10-02 2012-03-27 Mylan Inc. Method for making a multilayer adhesive laminate
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
US8920392B2 (en) * 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
KR101734602B1 (ko) 2009-10-21 2017-05-11 데이고꾸세이약꾸가부시끼가이샤 도네페질 함유 경피 흡수형 제제
EP2514440B1 (en) 2009-12-15 2017-03-29 Teikoku Seiyaku Co., Ltd. Transdermal preparation containing basic anti-inflammatory agent
US11607407B2 (en) 2010-04-13 2023-03-21 Relmada Therapeutics, Inc. Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
FR2972923B1 (fr) * 2011-03-25 2013-08-23 Urgo Lab Composition filmogene contenant un filtre solaire, son utilisation pour le traitement des cicatrices
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
ES3034911T3 (en) 2011-05-10 2025-08-26 Itochu Chemical Frontier Corp Non-aqueous patch
EP2708229B1 (en) 2011-05-10 2019-07-31 Itochu Chemical Frontier Corporation Non-aqueous patch
EP2734198A4 (en) * 2011-06-24 2015-04-15 Acenda Pharma Inc METHOD AND IMPROVED PHARMACEUTICAL COMPOSITION FOR IMPROVING THE ABSORPTION OF AN ESTER PRODRUG
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
WO2013046335A1 (ja) 2011-09-27 2013-04-04 伊藤忠ケミカルフロンティア株式会社 非水性貼付剤
US20140271796A1 (en) * 2011-10-26 2014-09-18 Hisamitsu Pharmaceutical Co., Inc. Oxybutynin-containing transdermal absorption preparation
US20130266643A1 (en) * 2012-04-10 2013-10-10 Hpo Life Sciences, Inc. Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis
KR102127625B1 (ko) * 2012-09-03 2020-06-29 다이이찌 산쿄 가부시키가이샤 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
SG11201501850VA (en) 2012-09-21 2015-04-29 Intensity Therapeutics Inc Method of treating cancer
US9072682B2 (en) 2012-12-31 2015-07-07 Mylan Inc. Transdermal dosage form for low-melting point active agent
CN103919754B (zh) * 2013-01-15 2018-11-06 江苏康倍得药业股份有限公司 奥昔布宁药物组合物及其应用
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
AR095258A1 (es) * 2013-03-14 2015-09-30 Noven Pharma Composiciones transdérmicas de metilfenidato con adhesivos a base de goma
WO2015139847A1 (en) * 2014-03-21 2015-09-24 Chironwells Gmbh 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament
US10149828B2 (en) 2015-01-09 2018-12-11 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP7397669B2 (ja) 2017-04-24 2023-12-13 チェイス セラピューティクス コーポレイション うつ病を治療するための組成物および方法
JP2019034905A (ja) * 2017-08-17 2019-03-07 コスメディ製薬株式会社 デヒドロ酢酸含有経皮吸収製剤
WO2019089523A1 (en) * 2017-10-30 2019-05-09 Theracaine Llc Hydrophobic acid addition salts and pharmaceutical formulations thereof
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
CN113384558A (zh) * 2021-02-01 2021-09-14 深圳普洛美康材料有限公司 一种递送大麻活性物质的透皮贴剂
JP2022122784A (ja) 2021-02-10 2022-08-23 コスメディ製薬株式会社 酸化防止剤含有経皮吸収製剤
KR20230026232A (ko) 2021-08-17 2023-02-24 신신제약 주식회사 옥시부티닌을 함유하는 경피흡수제제
CN113749968A (zh) * 2021-10-26 2021-12-07 奥易生物科技(杭州)有限公司 一种快速透皮吸收的化妆品及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466926A (en) * 1892-01-12 Advertising device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336262A (en) * 1973-02-23 1982-06-22 Fisons Ltd. Pour-on veterinary anthelmintic
EP0190262B1 (en) * 1984-07-24 1990-12-27 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4666926A (en) * 1986-02-27 1987-05-19 Warner-Lambert Company Transdermal formulations
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
JPH0676327B2 (ja) * 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイド軟膏製剤
US4857313A (en) * 1987-05-28 1989-08-15 Warner-Lambert Company Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4789547A (en) * 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
JP2526256B2 (ja) * 1987-11-17 1996-08-21 清水建設株式会社 構造物の振動抑制装置
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
DE3913954A1 (de) * 1989-04-27 1990-10-31 Stief Georg Arzneimittel zur behandlung erektiler dysfunktionen
EP0612526A4 (en) * 1991-11-15 1995-08-02 Ss Pharmaceutical Co ANTI-INFLAMMATORY AND ANALGETIC PLASTER.
JP3130350B2 (ja) * 1991-11-28 2001-01-31 積水化学工業株式会社 経皮吸収製剤
TW224048B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-03-30 1994-05-21 Hoechst Roussel Pharma
JPH08501529A (ja) * 1992-06-11 1996-02-20 セラテック・インコーポレイテッド 皮膚透過薬剤投与緩和のグリセリン使用
JPH08245377A (ja) * 1995-03-15 1996-09-24 Yamanouchi Pharmaceut Co Ltd 経皮吸収用製剤
JPH09309783A (ja) * 1996-05-20 1997-12-02 Chisso Corp 改良された土中崩壊型被覆粒状肥料

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466926A (en) * 1892-01-12 Advertising device

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101975677B1 (ko) 2017-11-20 2019-05-07 양진석 환편기용 보풀 제거장치
KR20200047437A (ko) 2018-10-26 2020-05-07 경상대학교산학협력단 아세틴 화합물의 생물학적 제조 방법

Also Published As

Publication number Publication date
CN1182358A (zh) 1998-05-20
CA2217888C (en) 2001-08-28
AU696777B2 (en) 1998-09-17
KR19990007786A (ko) 1999-01-25
NL300200I1 (nl) 2005-09-01
WO1996033678A1 (en) 1996-10-31
JP3228341B2 (ja) 2001-11-12
CN1714867A (zh) 2006-01-04
EP0871420B1 (en) 2001-09-19
ATE205694T1 (de) 2001-10-15
CN1507918A (zh) 2004-06-30
ZA963229B (en) 1997-01-28
US5601839A (en) 1997-02-11
AU5446796A (en) 1996-11-18
DK0871420T3 (da) 2002-01-21
HK1084320A1 (zh) 2006-07-28
NZ306249A (en) 2000-03-27
JPH10507199A (ja) 1998-07-14
CN1143688C (zh) 2004-03-31
US5834010A (en) 1998-11-10
PT871420E (pt) 2002-03-28
DE69615399D1 (de) 2001-10-25
DE122005000013I1 (de) 2005-06-23
ES2163012T3 (es) 2002-01-16
CN100374161C (zh) 2008-03-12
EP0871420A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1998-11-11
AR001721A1 (es) 1997-11-26
DE69615399T2 (de) 2003-01-30
CA2217888A1 (en) 1996-10-31
JP2001039865A (ja) 2001-02-13
JP4511691B2 (ja) 2010-07-28
FR05C0008I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2007-05-25
MX9707868A (es) 1997-11-29
EP0871420A1 (en) 1998-10-21
FR05C0008I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-04-29

Similar Documents

Publication Publication Date Title
KR100275593B1 (ko) 경피 침투 강화제로써 트리아세틴
AU677206B2 (en) The use of glycerin in moderating transdermal drug delivery
JP2550441B2 (ja) 皮膚透過性促進組成物
EP1163902B1 (en) Transdermal preparation containing hydrophilic or salt-form drug
CA2277367A1 (en) Transdermal therapeutic system
KR20000068029A (ko) 제약학적 물질염을 경피 수송하기 위한 압력 감응성 접착제
PT96059B (pt) Sistema de camada unica para a administracao de um medicamento por via transdermica
WO1992020377A1 (en) Skin permeation enhancer compositions using glycerol monolinoleate
TW201431572A (zh) 荷爾蒙及其它醫藥劑之經皮傳遞的組成物及方法
PT1589973E (pt) FORMULAÆO E MéTODOS PARA O TRATAMENTO DE TROMBOCITEMIA
EP1229909A2 (en) Transdermal delivery of lasofoxifene
JP3980634B2 (ja) 活性物質モルフィン−６−グルクロニドを含む全身的経皮投与用医薬組成物
AU628660B2 (en) Transdermal delivery (+)(2s,3s)-3-acetoxy-8-chloro-5- (2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl) -1,5-benzothiazepin-4-(5h)-one
EP1711170B1 (en) Transdermal delivery device for dihydropyridine type calcium antagonists containing two fatty acids
KR100439659B1 (ko) 툴로부테롤을 함유하는 경피흡수용 패취제
HK1084320B (en) Triacetin as a transdermal penetration enhancer
MXPA97007868A (es) La triacetina como incrementador de penetraciontransdermica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19971016

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980108

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19991027

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20000105

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19991027

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20000406

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20000105

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20000630

Appeal identifier: 2000101000741

Request date: 20000406

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20000504

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20000406

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 19991220

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19980108

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20000630

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20000530

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20000922

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20000923

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20030915

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20040916

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20050916

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20060919

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20070918

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20080922

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20090918

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20100907

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20110906

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20120906

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20120906

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20130910

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20130910

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20150908

Year of fee payment: 16

PR1001 Payment of annual fee

Payment date: 20150908

Start annual number: 16

End annual number: 16

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20161008

Termination category: Expiration of duration